Michelle is a first-year MBA student at MIT Sloan focused on innovation across mental health therapeutics and care delivery. Before business school, she spent six years in academia and biotech developing psychedelic-based therapies for psychiatric disorders. She scaled and managed UCSF’s Translational Psychedelic Research Program and later led Phase I–III clinical trials and early launch planning for an LSD-based treatment for anxiety and depression at MindMed, where she continues to consult on go-to-market and commercial strategy.
Alongside her operating experience, Michelle is involved in early-stage venture and company formation as a Venture Resident at Alix Ventures, an organizing member of MIT Sloan’s Healthcare Innovations Pitch Competition, and a finalist in Nucleate Boston’s 2025 Activator Program, collaborating with two MIT-trained neuroscientists on early company formation for a novel CNS circuit therapeutics platform.
